Lamotrigine induced seizures in juvenile myoclonic epilepsy

Betül Acar, Ersel Dağ*, Yakup Türkel

Department of Neurology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey

Article History
Received 15/04/2013
Accepted 10/05/2013

* Correspondence to:
Ersel Dağ
Department of Neurology, Kırıkkale University, Kırıkkale, Turkey
e-mail: erseldag@yahoo.com

Keywords:
Antiepileptic drug
Seizure
Juvenile myoclonic epilepsy
Lamotrigine

1. Introduction
Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome accounts for 5 to 11% of all cases of epilepsy. Although it has quite typical clinical presentation and electroencephalographic (EEG) findings, patients of JME have often misdiagnosed and/or have delayed diagnosis (Atakli et al., 1998).

Valproate (VPA) is still the first choice antiepileptic drug in the treatment of primary JME. However, the use of VPA particularly in fertile age groups increases the risk of fetal malformation and may delay the neuronal development of the fetus (Duncan, 2007). Therefore, the usage of new generation antiepileptic drugs such as lamotrigine (LTG) levetiracetam, topiramate have been advocated especially in women (Auvin, 2008). However, LTG may increase the frequency of myoclonic and GTC seizures (Mantoan and Walker, 2011).

In this case report, it has been presented that 31-years-old female who was started VPA with the diagnosis of idiopathic generalized epilepsy and who experienced severe aggravation in myoclonic and generalized tonic-clonic seizures when LTG (50 mg/d) was prescribed in association to VPA (500 mg/d) after reduction of VPA therapy because of the side effects.

2. Case
Thirty-one-years-old female patient was taking 1000 mg/day VPA therapy with a diagnosis of idiopathic generalized epilepsy for more than ten years. The patient was admitted to a neurologist due to convulsions re-occurring. She had complaints of weight gain and hair loss. As she was in the period of fertility, the possible teratogenic side effects of VPA was also taken into account, VPA dose was reduced to 500 mg/day and LTG 50 mg/day was initiated.

During follow-up, under combination therapy the patient suffered from frequent convulsions which was required to visit the emergency department due to convulsions occurring every day. She admitted our clinic with these complaints. Twenty minutes after the admission to inpatient clinic, a GTC seizure was observed which was lasting about two minutes and followed by postictal confusion. Routine laboratory examinations were normal and postictal 2nd hour EEG revealed generalized spikes and multiple spike-slow wave paroxysms indicating JME (Fig. 1).

Due to increased complaints, the combination therapy was stopped and dose of VPA was increased gradually to 1500 mg / day after informing the patient and her husband about the potential side effects and teratogenicity. After treat-
ment with high dose VPA, she has been doing well without any seizures for 1 year follow-up. Under the treatment of high dose VPA therapy awake EEG was normal (Fig. 2).

3. Discussion

Although there are typical clinical and EEG findings exists for JME, patients are quite often misdiagnosed and appropriate treatment is delayed. Many patients do not mention about myoclonic jerks as they usually do not found as significant (Mehndiratta and Aggarwal, 2002). Our case also did not mentioned from myoclonic jerks, before admitted to our inpatient clinic. However, GTC and absence type seizures may accompany in 80 to 97% patients of JME (Mehndiratta and Aggarwal, 2002). We did not have knowledge about the previous EEGs of our patient.

Generalized spikes and multiple spike slow wave patterns were observed in short-term EEG recordings taken during the observation period in our clinic.

VPA is the first choice in the treatment of JME. If VPA therapy is ineffective or the patient is in the period of fertility, drugs such as LTG, levetiracetam and topiramate may be preferred (Mantoan and Walker, 2011). However, it has also been reported that LTG may increase the GTC and myoclonic seizures. LTG may be the cause of increased frequencies of GTC and myoclonic seizures in this case, in addition reduction of VPA may be another reason. Considering these probabilities we had decided to stop LTG with tapering the dose while simultaneously increasing VPA dose. During this regimen the seizures had disappeared and no increased side effects due to VPA was observed.

Bodenstein-Sachar et al. (2011) reported that respond to treatment with LTG is well in patients with JME without idiopathic generalized epilepsy.

Janszky et al. (2000) have reported that LTG was associated with increased rate in myoclonic jerks with increasing serum levels, both in LTG monotherapy and in the combination therapy with VPA, in patients with refractory idiopathic generalized epilepsy. Similarly our patient was also suffered from increased frequency of seizures when the combination of VPA and LTG was used.

Crespel et al. (2005) have observed that myoclonic jerks have emerged during treatment with LTG in the five patients with idiopathic generalized epilepsy. The seizures was stopped when the doses were decreased about 25-50% in three of the patients however for the remaining two patients, LTG therapy had to be stopped for cessation of the seizures.

In conclusion, clinicians should be aware that LTG may cause an increase in seizures in patients with JME when occurred together with GTC.

REFERENCES


